Immatics has founded a US subsidiary

Immatics GmbH founds $60m US T-cell spin-out

By Fiona BARRY

German biotech Immatics and the University of Texas have spent $60m on spin-out Immatics US to specialise in adoptive cellular therapies (ACT) for cancer.

The mAbs has been approved to begin clinical trials

CNS drugmaker teams with CDMO on ALS mAb candidate

By Fiona BARRY

CDMO (contract development and manufacturing organisation) Goodwin Biotechnology is working with CNS biotech Q Therapeutics to produce mAbs for a clinical trial to treat motor neuron disease.